Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction

American Journal of Cardiology

Volumn 119, Issue 11, 2017, Pages 1785-1790

  O'Neal, Wesley T ^a   Sandesara, Pratik ^a   Hammadah, Muhammad ^a   Venkatesh, Sanjay ^b   Samman Tahhan, Ayman ^a   Kelli, Heval M ^a   Soliman, Elsayed Z ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADVERSE OUTCOME; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEX DIFFERENCE; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; GLOBAL HEALTH; HEART FAILURE; HEART STROKE VOLUME; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; STROKE; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

AGED; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GLOBAL HEALTH; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SPIRONOLACTONE; STROKE; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85017151479     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.02.045     Document Type: Article

References (21)

1. 1 Yancy, C.W., Lopatin, M., Stevenson, L.W., De Marco, T., Fonarow, G.C., ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47 (2006), 76–84.
2. 2 Oktay, A.A., Rich, J.D., Shah, S.J., The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 10 (2013), 401–410.
3. 3 Bursi, F., Weston, S.A., Redfield, M.M., Jacobsen, S.J., Pakhomov, S., Nkomo, V.T., Meverden, R.A., Roger, V.L., Systolic and diastolic heart failure in the community. JAMA 296 (2006), 2209–2216.
4. 4 Zakeri, R., Chamberlain, A.M., Roger, V.L., Redfield, M.M., Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128 (2013), 1085–1093.
5. 5 Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994), 840–844.
6. 6 Olsson, L.G., Swedberg, K., Ducharme, A., Granger, C.B., Michelson, E.L., McMurray, J.J., Puu, M., Yusuf, S., Pfeffer, M.A., CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47 (2006), 1997–2004.
7. 7 McManus, D.D., Hsu, G., Sung, S.H., Saczynski, J.S., Smith, D.H., Magid, D.J., Gurwitz, J.H., Goldberg, R.J., Go, A.S., Cardiovascular Research Network PRESERVE Study. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc, 2, 2013, e005694.
8. 8 Eapen, Z.J., Greiner, M.A., Fonarow, G.C., Yuan, Z., Mills, R.M., Hernandez, A.F., Curtis, L.H., Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 167 (2014), 369–375.e362.
9. 9 Lam, C.S., Donal, E., Kraigher-Krainer, E., Vasan, R.S., Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 13 (2011), 18–28.
10. 10 Soliman, E.Z., Safford, M.M., Muntner, P., Khodneva, Y., Dawood, F.Z., Zakai, N.A., Thacker, E.L., Judd, S., Howard, V.J., Howard, G., Herrington, D.M., Cushman, M., Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 174 (2014), 107–114.
11. 11 O'Neal, W.T., Sangal, K., Zhang, Z.M., Soliman, E.Z., Atrial fibrillation and incident myocardial infarction in the elderly. Clin Cardiol 37 (2014), 750–755.
12. 12 Olesen, J.B., Torp-Pedersen, C., Hansen, M.L., Lip, G.Y., The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 107 (2012), 1172–1179.
13. 13 Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., Silbershatz, H., Kannel, W.B., Levy, D., Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998), 946–952.
14. 14 Friberg, J., Scharling, H., Gadsboll, N., Truelsen, T., Jensen, G.B., Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94 (2004), 889–894.
15. 15 Pitt, B., Pfeffer, M.A., Assmann, S.F., Boineau, R., Anand, I.S., Claggett, B., Clausell, N., Desai, A.S., Diaz, R., Fleg, J.L., Gordeev, I., Harty, B., Heitner, J.F., Kenwood, C.T., Lewis, E.F., O'Meara, E., Probstfield, J.L., Shaburishvili, T., Shah, S.J., Solomon, S.D., Sweitzer, N.K., Yang, S., McKinlay, S.M., TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
16. 16 Desai, A.S., Lewis, E.F., Li, R., Solomon, S.D., Assmann, S.F., Boineau, R., Clausell, N., Diaz, R., Fleg, J.L., Gordeev, I., McKinlay, S., O'Meara, E., Shaburishvili, T., Pitt, B., Pfeffer, M.A., Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162 (2011), 966–972.e910.
17. 17 Shah, S.J., Heitner, J.F., Sweitzer, N.K., Anand, I.S., Kim, H.Y., Harty, B., Boineau, R., Clausell, N., Desai, A.S., Diaz, R., Fleg, J.L., Gordeev, I., Lewis, E.F., Markov, V., O'Meara, E., Kobulia, B., Shaburishvili, T., Solomon, S.D., Pitt, B., Pfeffer, M.A., Li, R., Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 6 (2013), 184–192.
18. 18 Pfeffer, M.A., Claggett, B., Assmann, S.F., Boineau, R., Anand, I.S., Clausell, N., Desai, A.S., Diaz, R., Fleg, J.L., Gordeev, I., Heitner, J.F., Lewis, E.F., O'Meara, E., Rouleau, J.L., Probstfield, J.L., Shaburishvili, T., Shah, S.J., Solomon, S.D., Sweitzer, N.K., McKinlay, S.M., Pitt, B., Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
19. 19 Heidenreich, P.A., Albert, N.M., Allen, L.A., Bluemke, D.A., Butler, J., Fonarow, G.C., Ikonomidis, J.S., Khavjou, O., Konstam, M.A., Maddox, T.M., Nichol, G., Pham, M., Pina, I.L., Trogdon, J.G., American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
20. 20 Odden, M.C., Coxson, P.G., Moran, A., Lightwood, J.M., Goldman, L., Bibbins-Domingo, K., The impact of the aging population on coronary heart disease in the United States. Am J Med 124 (2011), 827–833.
21. 21 Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., Singer, D.E., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001), 2370–2375.